What is the interpretation of a QuantiFERON‑Gold TB1 minus NIL (TB1‑NIL) result of 0.41 IU/mL?

QuantiFERON-TB Gold TB1-NIL Result of 0.41 IU/mL Interpretation

A TB1-NIL result of 0.41 IU/mL is POSITIVE for Mycobacterium tuberculosis infection according to FDA-approved criteria, as it exceeds the 0.35 IU/mL cutoff threshold. 1

Understanding the Result

The TB Response (TB1-NIL in this case) represents the interferon-gamma concentration released when blood is stimulated with TB-specific antigens (ESAT-6, CFP-10, and TB7.7) minus the background interferon-gamma in the unstimulated (Nil) tube. Your result of 0.41 IU/mL falls into the borderline positive zone (0.35-0.7 IU/mL), which requires careful clinical interpretation.

Critical Context: The Borderline Zone Problem

While technically positive, your result sits in a range where test variability is significant:

• Values between 0.35-0.7 IU/mL show substantial test-retest variability 2, 3
• In one large study, 38.3% of borderline results (0.20-0.99 IU/mL) reverted to convincingly negative (<0.20 IU/mL) on repeat testing, with no cases developing active TB within 2 years 4
• Technical and immunological variability is highest in this range, particularly with manual ELISA methods 3

Recommended Clinical Approach

Step 1: Assess Pre-Test Probability

Evaluate your actual risk of TB exposure:

• High-risk indicators: Recent contact with active TB case, immigration from high-burden country within 5 years, HIV infection, immunosuppression, healthcare worker with occupational exposure
• Low-risk indicators: No known TB exposure, born in low-incidence country, no immunocompromising conditions

Step 2: Consider Confirmatory Testing

For borderline results (0.35-0.7 IU/mL), repeat testing with a new blood sample is strongly recommended 1, 2:

• If repeat test shows >0.7 IU/mL: This represents true infection with 10-fold higher TB disease risk 2
• If repeat test shows <0.2 IU/mL: This represents true negative; no treatment needed 2
• If repeat remains 0.2-0.7 IU/mL: Interpret based on clinical risk factors

Step 3: Check for Technical Issues

The guidelines recommend repeat testing when 1:

• Nil value is unusually high (>0.7 IU/mL for most U.S. populations)
• Testing interval was short (<6 months in serial testing programs)
• Mitogen response is low (<0.5 IU/mL), suggesting possible immune dysfunction

Clinical Decision Algorithm

If HIGH pre-test probability (known TB exposure, immunosuppressed, high-burden country origin):

• Treat as positive
• Evaluate for active TB (chest X-ray, symptoms, physical exam)
• If active TB excluded, offer LTBI treatment 1

If LOW pre-test probability (no risk factors, incidental screening):

• Obtain confirmatory test with new blood sample
• If repeat <0.2 IU/mL: No treatment needed
• If repeat >0.7 IU/mL: Treat as true positive
• If repeat remains borderline: Consider no treatment given low risk 1

If INTERMEDIATE risk:

• Repeat testing is essential
• Consider TST as additional confirmatory test if IGRA remains borderline 1
• Decision should incorporate epidemiologic history and clinical judgment

Important Caveats

• This test cannot distinguish latent infection from active TB disease - anyone with positive results and symptoms (cough, fever, night sweats, weight loss) requires full evaluation for active TB 1
• Negative or borderline results do not exclude TB in high-risk individuals or those with clinical suspicion 1
• Recent exposure (<8-10 weeks): If exposure was recent, repeat testing at 8-10 weeks is needed regardless of initial result 5
• Children <5 years and severely immunocompromised patients: Negative results are particularly unreliable; clinical judgment supersedes test results 1

The Bottom Line

Your result of 0.41 IU/mL is technically positive but falls in the uncertainty zone where test variability is significant. The most evidence-based approach is confirmatory testing with a new blood sample before making treatment decisions, unless you have high-risk features that warrant immediate evaluation and treatment. The goal is to identify those with values >0.7 IU/mL (true infection with higher disease risk) versus those <0.2 IU/mL (true negative) 2.